Concert Pharma (CNCE) Posts Q2 EPS of $1.80

Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of $1.80, $2.26 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $3.25 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c